Navigation Links
Aethlon Medical Announces Engagement of RedChip Companies to Initiate Investor and Media Relations Programs

SAN DIEGO, April 21 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), developer of the Hemopurifier(R), a first-in-class medical device to treat infectious disease, today announced that it has hired RedChip Companies, Inc. to lead its investor relations outreach programs.


"We have created the first medical device that can selectively remove viruses from the bloodstream," stated James A. Joyce, chief executive officer of Aethlon Medical. "We plan to leverage RedChip's strong media, investor, and public relations platform to raise the visibility of our endeavors and expand our base of loyal shareholders," concluded Joyce. So far in 2009, the Aethlon Hemopurifier(R) has demonstrated significant viral load reductions in both Hepatitis-C (HCV) and HIV infected patients.

"We are thrilled to have the opportunity to represent Aethlon Medical, a company that is making such groundbreaking advances in the field of virus treatment," said Dave Gentry, president and chief executive officer of RedChip Companies, Inc. "We look forward to introducing Aethlon to RedChip's investor network as we launch a comprehensive investor relations program."

About Aethlon Medical

Aethlon Medical creates diagnostic and therapeutic filtration devices to improve the health of individuals afflicted with infectious disease and cancer. Aethlon's lead product, the Hemopurifier(R), is a first-in-class artificial adjunct to the immune system proven to capture infectious viruses and immunosuppressive particles from the human circulatory system. The device targets to inhibit disease progression of Hepatitis-C Virus (HCV) and Human Immunodeficiency Virus (HIV), and serves as a broad-spectrum treatment countermeasure against bioterror and emerging pandemic threats. The Hemopurifier(R) also holds promise in cancer care, as research studies verify the Hemopurifier(R) effectively captures immunosuppressive exosomes that are secreted by tumors to kill-off immune cells. At present, over sixty-five (65) Hemopurifier(R) treatments (representing approximately 260 hours of treatment time) have been conducted in multi-site studies at the Apollo Hospital, Fortis Hospital, and Sigma New-Life Hospital in India. The studies enrolled end-stage renal disease (ESRD) patients infected with either HCV or HIV. In addition to establishing treatment safety, robust viral load reductions have been reported in both HCV and HIV infected individuals.

Research studies have also demonstrated the Hemopurifier(R) is effective in capturing a broad-spectrum of viruses untreatable with drug therapy, including several of world's deadliest bioterror and pandemic threats. These include: Dengue hemorrhagic fever (DHF), Ebola hemorrhagic fever (EHF), Lassa hemorrhagic fever (LHF), H5N1 avian influenza (Bird Flu), the reconstructed 1918 influenza virus (r1918), West Nile virus (WNV), and Vaccinia and Monkeypox (MPV), which both serve as models for human smallpox infection. The studies were conducted with the assistance of researchers representing: The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID); The Centers for Disease Control and Prevention (CDC); The National Institute of Virology (NIV); The Battelle Biomedical Research Center (BBRC); and The Southwest Foundation for Biomedical Research (SFBR).

Beyond therapeutic market opportunities, Aethlon is leveraging principles underlying the Hemopurifier(R) technology platform to establish a pipeline of clinical and research diagnostic products and services. Additional information regarding Aethlon Medical can be accessed online at

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier(R) to reduce viral loads and other disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

SOURCE Aethlon Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Aethlon Medical Announces CEO Interview and Corporate Presentation Available Online
2. MSU engineering team designs innovative medical device
3. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
4. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
5. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
6. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
7. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
8. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
9. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
10. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
11. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
Post Your Comments:
(Date:11/30/2015)... NC (PRWEB) , ... November 30, 2015 , ... ... practices in 2016. In 2016, expected coding changes are likely to include new ... service codes. It’s not easy to understand the effects of code changes in ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... Bayco Products, Inc today announced the introduction ... each. Available in a choice of three different colors; red ( NSP-1632 ), yellow ( ... run up to 18 hours in constant-on mode, or 27 hours in blinking strobe mode ...
(Date:11/29/2015)... ... November 30, 2015 , ... Gift ideas for the natural ... All products are available on Amazon or its webstore. , "We love the ... USDA Certified Organic Sesame Oil for Oil Pulling," says Kathy Heshelow, founder of ...
(Date:11/29/2015)... Orion, Clarkston, Metamora, Michigan (PRWEB) , ... November 29, 2015 , ... ... football games, basketball games. Things that as a Mother and Wife would love to ... was no mistake that I just happened to call Dr. Zaidan first. They have ...
(Date:11/29/2015)... ... ... NewsWatch featured X-wing as part of its monthly Tech Report, which features the ... special reporter for NewsWatch, conducted the review and shared with viewers how Woody Guthrie’s ... flying cars are about to become a reality. Where’s the idea from? With inspiration ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 2015   Nuance Communications, Inc. (NASDAQ: ... Company (NDSC) today jointly announced a new integrated ... utilize the American College of Radiology,s (ACR) Imaging 3.0™ ... comply with current and emerging value-based payment models ... By combining clinical decision support, radiology reporting and ...
(Date:11/30/2015)... N.J. , Nov. 30, 2015  Novartis will ... at the 57 th American Society of Hematology ... lymphomas and myelomas as well as supportive care, including ... addition to personalized cell therapies. The ASH Annual Meeting ... Florida . Novartis Oncology . "We ...
(Date:11/30/2015)... REHOVOT, Israel , Nov. 30, 2015 ... focused on acquiring and developing innovative therapies for ear, ... of Keith A. Katkin as chairman of ... Flesher , chief executive officer for OticPharma, Ltd.  "Keith ... As chairman, he will be able to share this ...
Breaking Medicine Technology: